Stock AnalizHarmony Biosciences Holdings, Inc. HRMY
Biotechnology: Pharmaceutical Preparations · IPO 2020 · data as of November 13, 2026
Harmony Biosciences Holdings, Inc. (HRMY) is a healthcare company listed in the US with a market value of about $2.0B. In the twelve months to September 30, 2026 it had revenue of $989M and net income of $179M, a net margin of 18.1%.
Its overall Stock Analiz score is 3.8 out of 5 (good). The strongest part is financial health (5/5); the weakest is shareholder returns (2/5).
Key numbers: a P/E of 11.1, a price to free cash flow of 6.1, 5-year revenue growth of 40% a year, a 5-year average ROIC of 18%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 291% above the current price.
Score: 3.8 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
Checks not passed
- PEG below 1.5
- Profit margin improving
- 5-year EPS growth above 10% a year
- Pays a dividend
- 20% to 100% of free cash flow returned to shareholders
- Dividend 3 years in a row
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $989M | $868M | $715M | $582M | $438M | $305M | $160M | $6M |
| Net income | $179M | $159M | $145M | $129M | $181M | $35M | -$37M | -$152M |
| Free cash flow | $323M | $348M | $219M | $219M | $144M | $98M | -$3M | -$76M |
| EPS (diluted) | $3.03 | $2.71 | $2.51 | $2.13 | $2.97 | $0.58 | $-2.48 | $-24.07 |
| Net margin | 18.1% | 18.3% | 20.4% | 22.1% | 41.4% | 11.3% | -23.1% | -2535.1% |
| ROIC | — | 14.8% | 17.2% | 21.5% | 15.9% | 20.8% | 4.6% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 12 analysts is $48.08, 42% above the current price; targets range from $32.00 to $70.00; the consensus rating is “Buy”; expected EPS is $4.76 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Harmony Biosciences’s P/E ratio?
About 11.1, based on the last twelve months of diluted earnings per share (forward P/E about 6.3).
Is Harmony Biosciences stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 291% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Harmony Biosciences pay a dividend?
Not currently.
Is Harmony Biosciences a good stock to buy?
We do not give buy or sell advice. Harmony Biosciences scores 3.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.